Chongqing Lummy Pharmaceutical (300006.SZ) stated on the investor interaction platform on June 12 that the company holds 0.75% equity of Replicor Inc through its wholly-owned subsidiary Laimai Hong Kong. Replicor's hepatitis B drug development project is currently progressing steadily. The company will closely monitor the follow-up progress of the project and fulfill its information disclosure obligations in a timely manner in accordance with relevant regulations of the Shenzhen Stock Exchange.
莱美药业(300006.SZ)：Replicor公司乙肝药物开发项目目前处于稳步推进中
Chongqing Lummy Pharmaceutical (300006.SZ): The Replicor hepatitis B drug development project is currently steadily progressing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.